Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price & Analysis
Amphastar Pharmaceuticals, Inc. (AMPH) fell 0.79% to USD 18.72 as of July 25, 2026 at 05:27 UTC, according to Nexqual real-time market data.
AMPH last closed at USD 18.87; the session ranged USD 18.54–19.12 on volume of 428,735 shares. Market capitalization is $825.42M, with a 52-week range of USD 16.65–31.26 (NMS). Source: Nexqual, July 25, 2026 at 05:27 UTC.
Key Statistics (as of July 25, 2026 at 05:27 UTC)
| Price | USD 18.72 |
|---|---|
| Change | ▼ 0.79% (down) |
| Previous Close | USD 18.87 |
| Open | USD 18.9 |
| Day Range | USD 18.54 – 19.12 |
| 52-Week Range | USD 16.65 – 31.26 |
| Volume | 428,735 shares |
| Market Cap | $825.42M |
| Exchange | NMS |
Technical Analysis (AMPH)
Nexqual's technical model rates AMPH "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.47 (neutral) |
| vs SMA50 | Below (USD 19.24) |
| MACD | -0.16 (negative) |
Analyst Ratings (AMPH)
Wall Street analysts rate AMPH "Hold" based on 6 analysts, with a mean price target of USD 22 (range USD 19–30), per Nexqual as of July 25, 2026 at 05:27 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 22 |
| High Target | USD 30 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 0 / 6 / 1 |
Earnings (AMPH)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.62 |
| Revenue Estimate | $180.26M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.42 vs est 0.71 ▼ miss |
| 2025-12-31 | USD 0.73 vs est 0.92 ▼ miss |
| 2025-09-30 | USD 0.93 vs est 0.83 ▲ beat |
| 2025-06-30 | USD 0.85 vs est 0.74 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
Financials & Fundamentals (AMPH)
| Total Revenue | $720.53M |
|---|---|
| Revenue Growth (YoY) | +0.40% |
| Gross Margin | +47.34% |
| Operating Margin | +7.96% |
| Profit Margin | +11.00% |
| ROE | +10.39% |
| Debt / Equity | 88.75 |
| Current Ratio | 3.85 |
| Total Cash | $291.95M |
| Total Debt | $686.38M |
| Free Cash Flow | $103.10M |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
Financial Health Score (AMPH)
Nexqual rates Amphastar Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:27 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 8% |
| Balance Sheet | Mixed — $292M cash vs $686M debt |
| Cash Flow | Solid — FCF $103M, 14% margin |
| Efficiency | Mixed — ROE 10%, ROA 5.3% |
Ownership (AMPH)
| Insider Ownership | +29.76% |
|---|---|
| Institutional Ownership | +77.28% |
| Shares Outstanding | 44.09M |
| Float | 32.83M |
| Short % of Float | +18.25% |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
Leadership (AMPH)
Amphastar Pharmaceuticals, Inc. is led by Yongfeng Zhang (age 78), Co-Founder, President, CEO, Chief Scientific Officer & Director, per Nexqual as of July 25, 2026 at 05:27 UTC.
| Co-Founder, President, CEO, Chief Scientific Officer & Director | Yongfeng Zhang (age 78) |
|---|---|
| Chairman of the Board, Chief Scientist & COO | Ziping Luo (age 75) |
| CFO, Executive VP of Finance, Treasurer & Director | William J. Peters (age 57) |
| Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director | Jacob Liawatidewi (age 51) |
| Senior Vice President of Human Resources & Corporate Communication | Dan Dischner |
Major Backers & Investors (AMPH)
Notable institutional backers of Amphastar Pharmaceuticals, Inc. include American Century Companies Inc, TD Asset Management, Inc, Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund, according to Nexqual as of July 25, 2026 at 05:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 4.58% |
| TD Asset Management, Inc | 3.49% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 3.24% |
| Fuller & Thaler Asset Management Inc. | 3.16% |
| Boston Trust Walden Corporation | 3.01% |
| Marshall Wace LLP | 2.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 19.12% |
| Vanguard Group | 6.92% |
| Dimensional Fund Advisors | 4.6% |
| State Street | 4.35% |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
From Amphastar Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
- It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
- In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease.
- Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COLL | Collegium Pharmaceutical, Inc. | USD 35.2 | ▲ 1.38% |
| ANIP | ANI Pharmaceuticals, Inc. | USD 77.65 | ▲ 0.05% |
| PCRX | Pacira BioSciences, Inc. | USD 25.88 | ▲ 1.13% |
| SUPN | Supernus Pharmaceuticals, Inc. | USD 46.2 | ▼ 1.58% |
| ANGO | AngioDynamics, Inc. | USD 13.59 | ▼ 1.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:27 UTC. This page is informational and not investment advice.